Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma
NCT00003810Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Aug 1999
- Primary completion
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in pancreatic adenocarcinoma (PDAC), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Objective Response Rate, Toxicity Profile and 1 more. Started Aug 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00003810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003810.